Senolytics are a class of compounds designed to target and eliminate senescent cells, which are damaged or aged cells that no longer divide but remain in the body. These cells release harmful substances that can contribute to inflammation, tissue damage, and age-related diseases.
How Senolytics Work
Senescent cells accumulate with age, disrupting the body’s natural processes and promoting chronic conditions like arthritis, cardiovascular diseases, and neurodegenerative disorders. Senolytics work by selectively inducing apoptosis (programmed cell death) in these cells without harming healthy ones. By clearing senescent cells, senolytics aim to rejuvenate tissues, reduce inflammation, and improve overall healthspan.
Why Take Senolytics?
The promise of senolytics lies in their potential to slow aging and alleviate age-related diseases. Studies in animal models have shown significant improvements in physical function, reduced inflammation, and increased lifespan after senolytic treatment. While human trials are still in early stages, preliminary results suggest they could improve health outcomes, especially for those with chronic conditions linked to aging.
Cost and Availability
Currently, senolytics are not widely available as FDA-approved treatments but can be accessed in limited forms through research compounds or off-label use of drugs like dasatinib (a cancer drug) and quercetin (a natural flavonoid). These are often used in combination for their synergistic effects. Costs vary, with dasatinib being more expensive (around $50–$100 per dose) compared to quercetin supplements, which are generally under $30 for a month’s supply.
Emerging startups and biotech companies are working to develop proprietary senolytic therapies, which may lead to more accessible options in the coming years.
The Future of Senolytics
As research progresses, senolytics could play a transformative role in healthcare, offering new ways to manage aging and improve quality of life. However, more studies are needed to ensure their safety and efficacy in humans.
